Sucroferric oxyhydroxide (hyperphosphataemia in children and adolescents 2 years of age and older with CKD stages 4-5 or with CKD on dialysis) - Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Sucroferric oxyhydroxide (hyperphosphataemia in children and adolescents 2 years of age and older with CKD stages 4-5 or with CKD on dialysis) - Benefit assessment according to §35a Social Code Book V

   published on

   15.03.2021

   Document type

   PDF document, 455 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 455 kB, EN, not accessible)
2. Dossier assessment

   Sucroferric oxyhydroxide (hyperphosphataemia in children and adolescents 2 years of age and older with CKD stages 4-5 or with CKD on dialysis) - Benefit assessment according to §35a Social Code Book V

   published on

   15.03.2021

   Document type

   PDF document, 633 kB, DE, not accessible

   Download file : Dossier assessment (PDF document, 633 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A20-120

Commission

Commission awarded on 14.12.2020 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Children's and adolescents' health

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

1. Dossier assessment

   Sucroferric oxyhydroxide - Benefit assessment according to §35a Social Code Book V (dossier assessment)

   Project no.

   A14-37

   Last updated

   02.01.2015

   Status: Commission completed